Latest Health Care News

Holista Colltech has raised $2.295 million through a share placement to two international investors, aiming to bolster its operations and balance sheet. The move highlights the company’s ongoing efforts to support growth across its health and wellness divisions.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Ramsay Health Care announces a fully franked ordinary distribution of AUD 2.9642 per security on its perpetual preference shares, reflecting a steady income stream for investors. The payment is scheduled for April 2026, subject to board and external approvals.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

Acorn Capital Investment Fund Limited reported a robust FY25 with a $9.67 million profit after tax, a significant leap from $1.77 million the prior year, while delivering a 15.1% portfolio return that outperformed its benchmark.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Salter Brothers Emerging Companies Limited posted a 25.5% decline in profit after tax for FY25 but marked a milestone with its inaugural dividend payment. The fund remains confident in its small-cap investment strategy amid easing interest rates and geopolitical volatility.

Ramsay Health Care has confirmed the payment of a fully franked ordinary dividend on its perpetual preference securities, clearing prior approval conditions and setting a payment date for October 2025.